N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-(6-phenylhexyl)guanidine

ID: ALA208620

Chembl Id: CHEMBL208620

PubChem CID: 11495588

Max Phase: Preclinical

Molecular Formula: C18H24ClN7O

Molecular Weight: 389.89

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  N/C(=N\C(=O)c1nc(Cl)c(N)nc1N)NCCCCCCc1ccccc1

Standard InChI:  InChI=1S/C18H24ClN7O/c19-14-16(21)25-15(20)13(24-14)17(27)26-18(22)23-11-7-2-1-4-8-12-9-5-3-6-10-12/h3,5-6,9-10H,1-2,4,7-8,11H2,(H4,20,21,25)(H3,22,23,26,27)

Standard InChI Key:  HXLRWHNZECIEOM-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA208620

   N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N''-(6-phenylhexyl)guanidine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 389.89

Molecular Weight (Monoisotopic): 389.1731

AlogP: 2.14

#Rotatable Bonds: 8

Polar Surface Area: 145.30

Molecular Species: NEUTRAL

HBA: 5

HBD: 4

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 7

#RO5 Violations (Lipinski): 1

CX Acidic pKa: ┄

CX Basic pKa: 7.46

CX LogP: 3.18

CX LogD: 2.85

Aromatic Rings: 2

Heavy Atoms: 27

QED Weighted: 0.31

Np Likeness Score: -0.43

References

1. Hirsh AJ, Molino BF, Zhang J, Astakhova N, Geiss WB, Sargent BJ, Swenson BD, Usyatinsky A, Wyle MJ, Boucher RC, Smith RT, Zamurs A, Johnson MR..  (2006)  Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis.,  49  (14): [PMID:16821771] [10.1021/jm051134w]

Source

Source(1):

• Scientific Literature